← Back to Screener
TransCode Therapeutics, Inc. Common Stock (RNAZ)
Price$8.70
Favorite Metrics
Price vs S&P 500 (26W)-31.07%
Price vs S&P 500 (4W)-12.52%
Market Capitalization$8.17M
All Metrics
Book Value / Share (Quarterly)$1.71
P/TBV (Annual)1.52x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-17.42
Price vs S&P 500 (YTD)27.81%
EPS (TTM)$-352.74
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-352.74
EPS (Annual)$-1317.21
ROI (Annual)-1130.17%
Cash / Share (Quarterly)$3.40
ROA (Last FY)-229.69%
EBITD / Share (TTM)$-59.18
Cash Flow / Share (Annual)$-363.48
P/B Ratio5.73x
P/B Ratio (Quarterly)6.28x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-200.41x
ROA (TTM)-319.39%
EPS Incl Extra (Annual)$-1317.21
Current Ratio (Annual)2.56x
Quick Ratio (Quarterly)1.02x
3-Month Avg Trading Volume0.18M
52-Week Price Return-21.22%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.42
52-Week High$22.03
EPS Excl Extra (Annual)$-1317.21
26-Week Price Return-27.09%
Quick Ratio (Annual)2.10x
13-Week Price Return12.08%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.60x
Enterprise Value$5.334
Revenue / Employee (Annual)$0
Cash / Share (Annual)$158.12
3-Month Return Std Dev98.88%
Net Income / Employee (TTM)$-4
ROE (Last FY)-1130.17%
Net Interest Coverage (Annual)-187.86x
EPS Basic Excl Extra (Annual)$-1317.21
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-352.74
ROI (TTM)-356.28%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.99
Price vs S&P 500 (52W)-51.05%
Year-to-Date Return30.45%
5-Day Price Return4.21%
EPS Normalized (Annual)$-1317.21
ROA (5Y Avg)-214.38%
Month-to-Date Return3.48%
Cash Flow / Share (TTM)$-13.32
EBITD / Share (Annual)$-1303.53
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-352.74
P/TBV (Quarterly)1.11x
P/B Ratio (Annual)2.52x
Book Value / Share (Annual)$2.62
Price vs S&P 500 (13W)11.39%
Beta1.53x
Revenue / Share (TTM)$0.00
ROE (TTM)-356.28%
52-Week Low$6.08
Analyst Recommendations
Mar 2025
Apr 2025
May 2025
Jun 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RNAZTransCode Therapeutics, Inc. Common Stock | — | — | — | — | $8.70 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
TransCode Therapeutics is a biopharmaceutical company developing cancer therapeutics and diagnostics. The company's lead candidate, TTX-MC138, is a nanoparticle-conjugated oligonucleotide in clinical development designed to inhibit metastatic tumor survival. If approved, the therapy aims to achieve durable disease regression and improve long-term patient survival outcomes.